$福泰制药(VRTX)$ Citi — Top-Quality Biotech Worth Chasing for a Strong Pipeline; New TP $305/share-CF franchise has a long tail with patent lasting until the mid-2030s. The next few quarters could be flat, keeping stock range-bound in the near term, Buy because of strong pipeline and multiple readouts. Catalysts: 2H’20 Ph 2 data VX-814 AATD; 2)2H’20 Ph 2 initiation VX-864 in AATD; 3) 2H’20 sNDA filing for Trikafta for patients 6-11 years; 2H’20/ 1H’20 potential Trikafta approval EU; 5) mid-2020 updates CTX001 SCD/beta-thal; 6)early-2021 initiation of type 1 diabetes program.

$西雅图遗传学(SGEN)$ BMO - Such performance supports our Outperform rating on shares and, along with Tukysa in HER2+ metastatic breast cancer, and a proven drug development engine, support SGEN as our top large-cap pick this year. raise the target price to $159 from $154.

$Arcturus医疗(ARCT)$ Baird - Despite the recent substantial upside, ARCT is still undervalued compared to competitors. -). Our current valuation for ARCT is under review, but we are enthusiastic about the RNA therapeutics firm's rapid blocking and tackling of LUNAR-COV19 development. Cormorant Asset Management also a notable buyer in the recent secondary offering at $17.